E. Brill‐Almon

发表

Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system.

O. Dym, J. Sussman, I. Silman, 2007, Plant biotechnology journal.

Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher disease

Atul Mehta, Pilar Giraldo, A. Mehta, 2016, American journal of hematology.

Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial

R. Schiffmann, R. Colvin, O. Goker-Alpan, 2019, Journal of inherited metabolic disease.

Human erythropoietin gene therapy for patients with chronic renal failure.

E. Galun, N. Casadevall, E. Podjarny, 2005, Blood.

Ex vivo transduction of human dermal tissue structures for autologous implantation production and delivery of therapeutic proteins.

N. Shani, A. Panet, E. Brill‐Almon, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.

Pilar Giraldo, Eugen Mengel, J. Szer, 2014, Blood cells, molecules & diseases.

A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme—A Preclinical and Phase I Investigation

E. Galun, S. Hashmueli, D. Aviezer, 2009, PloS one.

disease taliglucerase alfa , a novel enzyme replacement therapy for Gaucher expressed recombinant glucocerebrosidase , − Pivotal trial with plant cell

Gheona Altarescu, Atul Mehta, Pilar Giraldo, 2012 .

Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.

A. Mehta, S. Hashmueli, D. Aviezer, 2011, Blood.

Improving the accuracy of MRI spleen and liver volume measurements: a phase III Gaucher disease clinical trial setting as a model.

H. Ahmad, E. Brill‐Almon, L. Bracoud, 2011, Blood cells, molecules & diseases.

Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease.

C. Hollak, D. Aviezer, M. Maas, 2013, Blood cells, molecules & diseases.

Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R.

H. Soreq, T. Ben-Moshe, J. Atsmon, 2015, Toxicology and applied pharmacology.

Novel treatment for Fabry disease: IV administration of plant derived alpha-gal-A enzyme safety and efficacy interim report

R. Schiffmann, R. Colvin, O. Goker-Alpan, 2016 .

Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.

D. Elstein, A. Zimran, A. Abrahamov, 2015, Blood cells, molecules & diseases.

Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase

J. Szer, G. Pastores, A. Zimran, 2016, American journal of hematology.

Long-term efficacy and safety results of taliglucerase alfa through 5 years in adult treatment-naïve patients with Gaucher disease

F. Giona, A. Zimran, P. Cooper, 2016 .

Long Term Safety and Efficacy Data of Taliglucerase Alfa, a Plant Cell Expressed Recombinant Glucocerebrosidase, in Treatment Of Naïve Gaucher Disease Patients

A. Mehta, D. Elstein, A. Zimran, 2012 .

Switching from agalsidase alfa to pegunigalsidase alfa for treating Fabry disease: One year of treatment data from BRIDGE, a phase III open label study

K. Nicholls, D. Hughes, A. Linhart, 2020 .